Results 191 to 200 of about 34,275 (269)

Lability in Hittite and Indo‐European: A Diachronic Perspective

open access: yesStudia Linguistica, Volume 80, Issue 1, April 2026.
ABSTRACT Lability is defined as the possibility of a verb to enter a valency alternation without undergoing any change in its form. Labile verbs were common in ancient Indo‐European languages, including Hittite, which mostly features anticausative lability, with reflexive and reciprocal lability being less prominent.
Guglielmo Inglese
wiley   +1 more source

Variation in perceptions of pain and attitudes towards non‐steroidal anti‐inflammatory drug use for different lameness scenarios in dairy cattle

open access: yesVeterinary Record, Volume 198, Issue 7, Page e278-e286, 28 March–11 April 2026.
Abstract Background Lameness diagnosis and treatment have important welfare and production consequences in dairy farming. Methods A questionnaire examining factors affecting non‐steroidal anti‐inflammatory drug (NSAID) use and pain scores associated with 16 lameness scenarios was distributed among UK farmers, veterinarians, veterinary technicians and ...
Emily Craven   +3 more
wiley   +1 more source

Development of a proptosis model as a surgical training tool for veterinary students and practitioners

open access: yesVeterinary Record, Volume 198, Issue 7, Page e293-e298, 28 March–11 April 2026.
Abstract Background Effective training is fundamental to the development of critical skills for emergency veterinary interventions. This study presents a synthetic canine proptosis model designed to train veterinary interns, final‐year students and practitioners, offering an ethical, reproducible and high‐fidelity option for learning proptosis ...
Oren Pe'er, Lionel Sebbag, Ron Ofri
wiley   +1 more source

Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol

open access: yesInternational Journal of Cancer, Volume 158, Issue 6, Page 1617-1627, 15 March 2026.
What's new? PARP inhibitors are effective in patients with inactivating alterations in the BRCA1/2 genes across tumor types. However, the efficacy of PARP inhibitors in patients with other inactivated homologous recombination repair genes remains unclear. This knowledge gap and discrepancies in EMA/FDA approvals highlight the need for better biomarkers.
Ilse A. C. Spiekman   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy